CN1166365C - 阿仑膦酸的药物组合物及其在制备抑制人的骨吸收的药物中的用途 - Google Patents

阿仑膦酸的药物组合物及其在制备抑制人的骨吸收的药物中的用途 Download PDF

Info

Publication number
CN1166365C
CN1166365C CNB988074737A CN98807473A CN1166365C CN 1166365 C CN1166365 C CN 1166365C CN B988074737 A CNB988074737 A CN B988074737A CN 98807473 A CN98807473 A CN 98807473A CN 1166365 C CN1166365 C CN 1166365C
Authority
CN
China
Prior art keywords
alendronate
alendronic acid
pharmaceutically acceptable
pharmaceutical composition
acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CNB988074737A
Other languages
English (en)
Chinese (zh)
Other versions
CN1265035A (zh
Inventor
Ag
A·G·戴福蒂斯
��ɣ��˹��������
A·C·桑托拉二世
A·J·雅特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1166365(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN1265035A publication Critical patent/CN1265035A/zh
Application granted granted Critical
Publication of CN1166365C publication Critical patent/CN1166365C/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
CNB988074737A 1997-07-22 1998-07-17 阿仑膦酸的药物组合物及其在制备抑制人的骨吸收的药物中的用途 Ceased CN1166365C (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US60/053,351 1997-07-22
US60/053351 1997-07-22
US5353597P 1997-07-23 1997-07-23
US60/053,535 1997-07-23
US60/053535 1997-07-23
US9717590.5 1997-08-20
GB9717590.5 1997-08-20
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GB9717850.3 1997-08-22
US9717850.3 1997-08-22
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CNA2004100557346A Division CN1602879A (zh) 1997-07-22 1998-07-17 抑制骨吸收的方法
CNB2004100557350A Division CN1299689C (zh) 1997-07-22 1998-07-17 阿仑膦酸在制备抑制骨吸收药物中的用途

Publications (2)

Publication Number Publication Date
CN1265035A CN1265035A (zh) 2000-08-30
CN1166365C true CN1166365C (zh) 2004-09-15

Family

ID=27451690

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB988074737A Ceased CN1166365C (zh) 1997-07-22 1998-07-17 阿仑膦酸的药物组合物及其在制备抑制人的骨吸收的药物中的用途
CNB2004100557350A Expired - Lifetime CN1299689C (zh) 1997-07-22 1998-07-17 阿仑膦酸在制备抑制骨吸收药物中的用途
CNA2004100557346A Pending CN1602879A (zh) 1997-07-22 1998-07-17 抑制骨吸收的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNB2004100557350A Expired - Lifetime CN1299689C (zh) 1997-07-22 1998-07-17 阿仑膦酸在制备抑制骨吸收药物中的用途
CNA2004100557346A Pending CN1602879A (zh) 1997-07-22 1998-07-17 抑制骨吸收的方法

Country Status (31)

Country Link
EP (5) EP1175903A3 (https=)
JP (2) JP3479780B2 (https=)
KR (3) KR100391732B1 (https=)
CN (3) CN1166365C (https=)
AT (2) ATE209037T1 (https=)
AU (1) AU8493698A (https=)
BG (1) BG66282B1 (https=)
BR (1) BR9810779A (https=)
CA (1) CA2294595C (https=)
CY (2) CY1107535T1 (https=)
DE (6) DE01201911T1 (https=)
DK (2) DK1175904T3 (https=)
EA (1) EA004544B2 (https=)
EE (1) EE05603B1 (https=)
ES (3) ES2164447T3 (https=)
HK (4) HK1042230A1 (https=)
ID (1) ID24096A (https=)
IL (1) IL133535A0 (https=)
IS (3) IS5315A (https=)
LU (2) LU91222I2 (https=)
NL (2) NL300223I1 (https=)
NO (1) NO20000323L (https=)
NZ (1) NZ501807A (https=)
PL (1) PL195272B1 (https=)
PT (2) PT1175904E (https=)
SG (2) SG139556A1 (https=)
SI (1) SI0998292T1 (https=)
SK (1) SK932000A3 (https=)
TR (1) TR200000145T2 (https=)
UY (1) UY25950A1 (https=)
WO (1) WO1999004773A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038694A1 (en) 1998-12-25 2000-07-06 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions for treating osseous lesion in multiple myeloma
PL351674A1 (en) * 1999-05-21 2003-05-19 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
EP1114642B1 (en) * 1999-07-19 2010-01-06 Toray Industries, Inc. Drugs for periodontal diseases
AU2270101A (en) * 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
AU2580001A (en) 1999-12-20 2001-07-03 Merck & Co., Inc. Blister package for pharmaceutical treatment card
AU2001251432A1 (en) * 2000-04-07 2001-10-23 The Board Of Regents Of The University Of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use ofthe compositions as bisphosphate delivery systems with reduced gi toxicity
ES2394211T3 (es) 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos
SI1296689T1 (sl) * 2000-06-20 2006-08-31 Novartis Ag Nacin dajanja pacientu bisfosfonatov
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
BR0209360A (pt) * 2001-05-02 2004-06-08 Novartis Ag Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
KR20060058151A (ko) * 2002-05-10 2006-05-29 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
CA2539359A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
JPWO2005072747A1 (ja) * 2004-02-02 2007-09-13 小野薬品工業株式会社 骨吸収抑制剤
WO2007031785A2 (en) * 2005-09-16 2007-03-22 Selamine Ltd Bisphosphonate formulation
CA2820019A1 (en) * 2010-12-06 2012-06-14 Effrx Pharmaceuticals Sa Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
ATE122228T1 (de) * 1991-07-01 1995-05-15 Gergely Gerhard Verfahren zur herstellung einer pharmazeutischen zubereitung mit wenigstens zwei verschiedenen wirkstoffen und verwendung einer solchen zubereitung.
CZ282760B6 (cs) * 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
DK0648120T3 (da) * 1992-06-30 1998-01-19 Procter & Gamble Pharma Anvendelse af phosphonater til behandling af osteoporose
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
AU703887B2 (en) * 1995-06-06 1999-04-01 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
WO1997044017A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Effervescent bisphosphonate formulation

Also Published As

Publication number Publication date
WO1999004773A9 (en) 1999-10-28
HK1042232A1 (en) 2002-08-09
DE122007000063I1 (de) 2007-12-20
HK1024166A1 (en) 2000-10-05
ID24096A (id) 2000-07-06
PL338635A1 (en) 2000-11-06
EP1175904B8 (en) 2007-05-09
ES2253136T1 (es) 2006-06-01
IS7231A (is) 2004-04-21
DE69803291T2 (de) 2002-08-08
ATE209037T1 (de) 2001-12-15
DE69837450D1 (de) 2007-05-10
PL195272B1 (pl) 2007-08-31
EP0998292A2 (en) 2000-05-10
DE01201913T1 (de) 2007-02-08
BR9810779A (pt) 2000-07-25
CY1107535T1 (el) 2012-01-25
WO1999004773A2 (en) 1999-02-04
IS5315A (is) 1999-12-21
EA004544B1 (ru) 2004-06-24
EA004544B2 (ru) 2006-12-29
LU91364I2 (fr) 2007-11-12
CY2007022I1 (el) 2012-01-25
NL300292I1 (nl) 2007-11-01
PT1175904E (pt) 2007-04-30
DE69837450T2 (de) 2007-08-23
KR20030097611A (ko) 2003-12-31
EA200000151A1 (ru) 2000-10-30
NO20000323L (no) 2000-03-20
IL133535A0 (en) 2001-04-30
HK1042230A1 (en) 2002-08-09
ES2164447T3 (es) 2002-02-16
EP1175904A2 (en) 2002-01-30
HK1040494A1 (en) 2002-06-14
BG104093A (en) 2000-10-31
CN1299689C (zh) 2007-02-14
HK1040495A1 (en) 2002-06-14
LU91222I2 (fr) 2006-04-18
JP2005068010A (ja) 2005-03-17
ATE357921T1 (de) 2007-04-15
DK1175904T3 (da) 2007-05-07
IS7230A (is) 2004-04-21
CY2007022I2 (el) 2012-01-25
EE05603B1 (et) 2012-12-17
EP1175904B1 (en) 2007-03-28
PT998292E (pt) 2002-04-29
NL300223I1 (nl) 2006-04-03
DE122006000009I1 (de) 2006-06-14
EP1175903A2 (en) 2002-01-30
DE69803291D1 (de) 2002-02-21
KR20010022110A (ko) 2001-03-15
CA2294595A1 (en) 1999-02-04
DE01201911T1 (de) 2007-10-18
EP1132088A3 (en) 2002-04-24
KR100391732B1 (ko) 2003-07-16
SG109478A1 (en) 2005-03-30
JP2002502433A (ja) 2002-01-22
SK932000A3 (en) 2000-09-12
CN1602879A (zh) 2005-04-06
BG66282B1 (bg) 2013-01-31
EE200000040A (et) 2000-10-16
JP3479780B2 (ja) 2003-12-15
DK0998292T3 (da) 2002-05-13
TR200000145T2 (tr) 2000-05-22
CA2294595C (en) 2001-08-21
NO20000323D0 (no) 2000-01-21
SG139556A1 (en) 2008-02-29
NZ501807A (en) 2003-02-28
EP1151752A2 (en) 2001-11-07
WO1999004773A3 (en) 1999-04-15
EP1151752A3 (en) 2002-12-18
CN1602880A (zh) 2005-04-06
UY25950A1 (es) 2000-09-29
EP1132088A2 (en) 2001-09-12
ES2269014T1 (es) 2007-04-01
AU8493698A (en) 1999-02-16
CN1265035A (zh) 2000-08-30
KR20030097610A (ko) 2003-12-31
ES2269014T3 (es) 2007-05-01
EP1175903A3 (en) 2002-12-18
SI0998292T1 (en) 2002-04-30
EP1175904A3 (en) 2002-12-18
EP0998292B1 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
CN1166365C (zh) 阿仑膦酸的药物组合物及其在制备抑制人的骨吸收的药物中的用途
US6544967B2 (en) Method for inhibiting bone resorption
US6015801A (en) Method for inhibiting bone resorption
US6465443B2 (en) Method for inhibiting bone resorption
CN1919200A (zh) 抑制骨吸收的方法
HK1103223A (en) Method for inhibiting bone resorption
AU741818B2 (en) Method for inhibiting bone resorption
AU2451102A (en) Method for inhibiting bone resorption
MXPA00000789A (en) Method for inhibiting bone resorption
HUP0004653A2 (hu) Biszfoszfonátok alkalmazása csontreszorpció gátlására szolgáló gyógyszerkészítmények előállítására
AU2005227418A1 (en) Method for inhibiting bone resorption

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: MERCK & CO. INC.

Free format text: FORMER NAME OR ADDRESS: MERCK + CO., INC.

CP01 Change in the name or title of a patent holder

Address after: New jersey, USA

Patentee after: MERCK & Co.,Inc.

Address before: New jersey, USA

Patentee before: MERCK & Co.,Inc.

C35 Partial or whole invalidation of patent or utility model
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20071102

Decision number of declaring invalidation: 10569

C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: New jersey, USA

Patentee after: MERCK SHARP & DOHME Corp.

Address before: New jersey, USA

Patentee before: MERCK & Co.,Inc.

C35 Partial or whole invalidation of patent or utility model
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20071102

Decision number of declaring invalidation: 10569

Granted publication date: 20040915